Europe Prothrombin Complex Concentrate Market to Grow USD 398.9 Million at 10.9% CAGR till 2027; Rising Adoption of Advanced Bleeding Disorder Management Solutions to Fuel Growth: Fortune Business Insights™
Top Players Covered in the Europe Prothrombin Complex Concentrate Market Research Report are Takeda Pharmaceutical Company Limited (Tokyo, Japan), Kedrion S.p.A (Lucca, Italy), Grifols, S.A. (Barcelona, Spain), Sanquin (Amsterdam, The Netherlands), Octapharma AG (Lachen, Switzerland), CSL Limited (Melbourne, Australia) and other key market players.
February 09, 2021 04:48 ET
| Source:
Fortune Business Insights
Fortune Business Insights
Pune, India, Feb. 09, 2021 (GLOBE NEWSWIRE) -- The
Europe prothrombin complex concentrate market size is projected to reach USD 398.9 million by 2027, exhibiting a CAGR of 10.9% during the forecast period. The substantial advantages offered by prothrombin complex concentrate (PCC) will be the primary driving force behind this market’s growth, forecasts Fortune Business Insights™ in its report, titled “Europe Prothrombin Complex Concentrate Market Size, Share & Covid-19 Impact Analysis, By Product (4-factor PCC and 3-factor PCC), By Application (Acquired Coagulation Deficiency and Congenital Coagulation Deficiency and By End User (Hospitals & Ambulatory Surgical Centers, Specialty Clinics, and Others), 2020-2027”. PCC (factor IX complex) is a medication comprising blood clotting factors II, IX, and X, indicated for treating bleeding in patients with hemophilia B. This line of treatment offers a host of benefits, especially when compared to Fresh Frozen Plasma (FFP), a leading anticoagulation-reversal therapy.